Author: Zheng, Lu; Zhang, Lina; Huang, Jiamin; Nandakumar, Kutty Selva; Liu, Shuwen; Cheng, Kui
Title: Potential treatment methods targeting 2019-nCoV infection Cord-id: lqjvxm3w Document date: 2020_7_28
ID: lqjvxm3w
Snippet: The novel coronavirus, 2019-nCoV, has quickly spread across the world and pose serious threat to public health because it can infect people very easily. The major clinical symptoms of 2019-nCoV infection include fever, dry cough, myalgia, fatigue, and diarrhea. The 2019-nCoV belongs to the betacoronavirus family, and gene sequencing results demonstrate that it is a single-stranded RNA virus, closely related to Severe Acute Respiratory Syndrome CoV (SARS-CoV) and Middle East Respiratory Syndrome
Document: The novel coronavirus, 2019-nCoV, has quickly spread across the world and pose serious threat to public health because it can infect people very easily. The major clinical symptoms of 2019-nCoV infection include fever, dry cough, myalgia, fatigue, and diarrhea. The 2019-nCoV belongs to the betacoronavirus family, and gene sequencing results demonstrate that it is a single-stranded RNA virus, closely related to Severe Acute Respiratory Syndrome CoV (SARS-CoV) and Middle East Respiratory Syndrome CoV (MERS-CoV). It has been observed that the virus invades human body mainly through binding to angiotensin-converting enzyme 2 (ACE2) receptors similar to SARS-CoV and the main protease (Mpro) acts as a critical protease for digesting the polyprotein into functional polypeptides during the replication and transcription process of 2019-nCoV. In this review, we summarized the real-time information of 2019-nCoV treatment methods and mainly focused on the chemical drugs including lopinavir/ritonavir, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir and other potential innovative active molecules. Their potential targets, activity, clinical status and side effects are described. In addition, Traditional Chinese Medicine (TCM), Convalescent plasma therapy (CPT) and biological reagents available, as well as the promising vaccine candidates against 2019-nCoV are also discussed.
Search related documents:
Co phrase search for related documents- action possible mode and acute respiratory syndrome: 1, 2
- action possible mode and acute respiratory syndrome cov: 1, 2
- activation development and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- activation development and acute respiratory syndrome cov: 1, 2, 3, 4, 5, 6, 7, 8, 9
- active component and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
- active component and acute respiratory syndrome cov: 1, 2, 3, 4, 5
- active form and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active form and acute respiratory syndrome cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- active molecule and acute respiratory syndrome: 1, 2, 3, 4, 5
- active molecule and acute respiratory syndrome cov: 1, 2, 3
- active triphosphate and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- active triphosphate and acute respiratory syndrome cov: 1, 2, 3, 4, 5, 6, 7, 8, 9
- active triphosphate incorporation and acute respiratory syndrome: 1
- active triphosphate incorporation and acute respiratory syndrome cov: 1
- acute respiratory syndrome and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and long period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lopinavir antiviral effect: 1
- acute respiratory syndrome cov and long period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome cov and lopinavir antiviral effect: 1
Co phrase search for related documents, hyperlinks ordered by date